Krishna Institute of Medical Sciences LtdNSE: KIMS
Open the Krishna Institute of Medical Sciences Ltd page
Follow Krishna Institute of Medical Sciences LtdFree account. Get a note when Krishna Institute of Medical Sciences Ltd files.
Q1 FY27 results analysis · August 03, 2026

Krishna Institute of Medical Sciences Ltd (KIMS) Q1 FY27 Results Analysis: PAT Collapses 47%, Revenue Surges 35%

−56.0%PAT year on year, Rs. 37.40 Cr
Cofacto ResearchPublished August 03, 20262 min readNeutral read
Quick summary

Krishna Institute of Medical Sciences Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 1,179.50 Cr (+35.30% YoY) and PAT growth of -56.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 03, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 1,179.50 Cr (+35.30% YoY)
PAT (Q1)Rs. 37.40 Cr (-56.00% YoY)
EBITDA margin19.03% (-307 bps YoY)
EPS (Q1)Rs. 1.04 (-46.90% YoY)
Market capRs. 34,650.75 Cr
CMPRs. 824.80

Quarter Snapshot

Revenue grew 35.3% YoY to Rs.1,179.5 Cr, but PAT to owners collapsed 47.2% as new hospital ramp-up costs, high finance charges, and operating expense growth compressed EBITDA margin to 19.03% (down 307 bps YoY). The QIP of Rs.1,500 Cr raised in June provides a path to deleveraging, but margin recovery hinges on occupancy improvement at new facilities.

Key Investment Insights

Key Positives

  • Revenue grew 35.3% YoY to Rs.1,179.5 Cr, the highest quarterly print in the sequence.
  • EBITDA grew 16.5% YoY to Rs.224.4 Cr.
  • QIP of Rs.1,500 Cr raised on 19 June 2026, with Rs.1,000 Cr earmarked for debt repayment, strengthening the balance sheet.
  • Standalone PAT grew 13.1% YoY to Rs.66.5 Cr, with EBITDA margin of 24.44%.
  • Auditor gave an unmodified (clean) review opinion on both standalone and consolidated results.

Risk Factors

  • PAT to owners declined 47.2% YoY to Rs.41.5 Cr.
  • EBITDA margin compressed 307 bps YoY to 19.03%.
  • Finance costs rose 155.8% YoY to Rs.83.4 Cr, now 7.07% of revenue.
  • New hospitals (subsidiaries) dragged PAT by Rs.25.0 Cr, compared to a positive contribution of Rs.19.8 Cr in Q1FY26.
  • Employee costs grew 40.8% YoY and other expenses grew 45.0% YoY, both exceeding revenue growth.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.